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A safe and effective vaccine is a critical tool to control the COVID-19 pandemic. As of 25 June 2021, 23 vaccines had advanced to Stage 3 clinical trials1 and more than a dozen 
had been approved in multiple countries2. The BNT162b vaccine 
from Pfizer–BioNTech, for example, has been approved in about 
90 countries, while the ChAdOx1 nCoV-19 vaccine from Oxford–
AstraZeneca has the most country authorizations at 1152. At present, 
however, global vaccine distribution remains highly unequal, with 
much of the current supply directed toward high-income countries3.
Although effective and equitable distribution of COVID-19 
vaccines is a key policy priority, ensuring acceptance is just as 
important. Trust in vaccines as well as the institutions that admin-
ister them are key determinants of the success of any vaccination 
campaign4. Several studies have investigated willingness to take a 
potential COVID-19 vaccine in high-income countries5–10, and 
some studies have included middle-income countries3,11. Less is 
known, however, about vaccine acceptance in low-income coun-
tries where large-scale vaccination has yet to begin. Understanding 
the drivers of COVID-19 vaccine acceptance is of global concern, 
because a lag in vaccination in any country may result in the emer-
gence and spread of new variants that can overcome immunity con-
ferred by vaccines and prior disease12,13.
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Widespread acceptance of COVID-19 vaccines is crucial for achieving sufficient immunization coverage to end the global pan-
demic, yet few studies have investigated COVID-19 vaccination attitudes in lower-income countries, where large-scale vaccina-
tion is just beginning. We analyze COVID-19 vaccine acceptance across 15 survey samples covering 10 low- and middle-income 
countries (LMICs) in Asia, Africa and South America, Russia (an upper-middle-income country) and the United States, including 
a total of 44,260 individuals. We find considerably higher willingness to take a COVID-19 vaccine in our LMIC samples (mean 
80.3%; median 78%; range 30.1 percentage points) compared with the United States (mean 64.6%) and Russia (mean 30.4%). 
Vaccine acceptance in LMICs is primarily explained by an interest in personal protection against COVID-19, while concern about 
side effects is the most common reason for hesitancy. Health workers are the most trusted sources of guidance about COVID-19 
vaccines. Evidence from this sample of LMICs suggests that prioritizing vaccine distribution to the Global South should yield 
high returns in advancing global immunization coverage. Vaccination campaigns should focus on translating the high levels of 
stated acceptance into actual uptake. Messages highlighting vaccine efficacy and safety, delivered by healthcare workers, could 
be effective for addressing any remaining hesitancy in the analyzed LMICs.
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Our study complements the emerging global picture of COVID-
19 vaccine acceptance by focusing primarily on lower-income coun-
tries. We construct a sample of low- and middle-income countries 
(LMICs) with wide geographic coverage across Africa, Asia and 
Latin America. We move beyond documenting vaccine acceptance 
rates to collect and analyze data on the reasons for acceptance and 
hesitancy, which is critical for informing the design of effective vac-
cine distribution and messaging. A summary of the main findings, 
limitations and implications of the study is shown in Table 1.
Acceptance of childhood vaccination for common diseases—
such as measles (MCV), Bacille Calmette–Guérin (BCG) and diph-
theria, tetanus and pertussis (DTP)—is generally high in LMICs, 
providing grounds for optimism about the prospects for COVID-19 
vaccine uptake. Table 2 summarizes general vaccine acceptance14 
and coverage rates of childhood vaccines in 201815, prior to the cur-
rent pandemic, for the countries included in our study. Agreement 
on the importance of childhood vaccinations is markedly higher 
in the LMICs we study compared to Russia and the United States. 
However, existing studies on COVID-19 vaccine acceptance doc-
ument substantial variation, both across and within countries, 
including in settings with high acceptance of other vaccinations3,4,11.
The existing literature cites concern about COVID-19 vac-
cine safety, including the rapid pace of vaccine development, as a 
primary reason for hesitancy in higher-income settings3,5. Other 
reasons may feature more prominently in LMICs. For example, 
reported COVID-19 cases and deaths have been consistently lower 
in most LMICs relative to higher-income countries16–18. If individu-
als feel the risk of disease is less severe, they may be less willing 
to accept any perceived risks of vaccination19. Previous studies of 
healthcare utilization in LMICs have also highlighted factors such 
as negative perceptions of healthcare quality20, negative historical 
experiences involving foreign actors21,22, weak support from tradi-
tional leaders23 and mistrust in government24 as barriers to uptake, 
which could apply to COVID-19 vaccination as well.
Results
To promote vaccination against COVID-19, we need to know 
whether people are willing to take COVID-19 vaccines, the rea-
sons why they are willing or unwilling to do so, and the most 
trusted sources of information in their decision-making. Our 
study investigates these questions using a common set of survey 
items deployed across 13 studies in Africa, South Asia and Latin 
America (Table 3): seven surveys in low-income countries (Burkina 
Faso, Mozambique, Rwanda, Sierra Leone and Uganda), five sur-
veys in lower-middle-income countries (India, Nepal, Nigeria and 
Pakistan) and one in an upper-middle-income country (Colombia). 
We compare these findings to those from two countries at the fore-
front of vaccine research and development, Russia (upper-middle 
income) and the United States (high income).
To select studies to include in our sample, we conducted an 
internal search within Innovations for Poverty Action (IPA), the 
International Growth Center (IGC) and the Berlin Social Science 
Center (WZB) for projects with plans to collect survey data in the 
second half of 2020. Study investigators agreed to include a set of 
common questions about COVID-19 vaccine attitudes. This strat-
egy was guided by the need to collect information quickly and 
cost-effectively using a survey modality (phone) that was both safe, 
given pandemic conditions, and appropriate for contexts with lim-
ited internet coverage. The final set of samples included in our study 
therefore reflects populations that fall under the current research 
priorities at IGC, IPA and WZB and, in the case of IPA and IGC, 
donors that prioritize working in the Global South.
Our main results are shown in Fig. 1 and are reproduced as 
Supplementary Table 1. The first column provides overall accep-
tance rates in each study, while the remaining columns disaggre-
gate acceptance by respondent characteristics. The ‘All LMICs’ row 
reports averages for the LMIC samples included in our study and 
excludes Russia and the United States. The ‘All LMICs (national 
samples)’ row reports averages for just the LMIC samples with 
national-level geographic coverage.
The average acceptance rate across the full set of LMIC studies 
is 80.3% (95% confidence interval (CI) 74.9–85.6%), with a median 
of 78%, range of 30.1 percentage points (pp) and interquartile range 
of 9.7 pp. Our estimate of the between-study standard deviation τ, 
using a random effects meta-analysis model, is 0.084, which repre-
sents only 10.5% of our estimate of the average acceptance across 
LMIC studies.
The acceptance rate in every LMIC sample is higher than in 
the United States (64.6%, CI 61.8–67.3%) and Russia (30.4%, CI 
29.1–31.7%). Reported acceptance is lowest in Burkina Faso (66.5%, 
CI 63.5–69.5%) and Pakistan (survey 2; 66.5%, CI 64.1–68.9%). 
Pakistan’s relatively low acceptance rate could be linked to negative 
historical experiences with foreign-led vaccination campaigns22,25,26. 
This hesitancy may be particularly problematic given the magni-
tude of the second wave in neighboring India and the acceleration 
of cases across South Asia that threatens to overwhelm health infra-
structure. The relatively low acceptance rate in Burkina Faso might 
reflect general vaccine hesitancy. As shown in Table 2, fewer people 
believe that vaccines in general are safe in Burkina Faso than in any 
other country included in our study, except Russia.
We find limited evidence of variation across demographic 
subgroups in our aggregate analysis of LMIC samples, as shown 
in Supplementary Table 2. Women are generally less willing to 
accept the vaccine than men (average difference about 4.2 points, 
Table 1 | Policy summary
Background We analyze COVID-19 vaccine acceptance and 
hesitancy and their drivers across 15 survey samples 
covering 10 LMICs in Asia, Africa and south 
America, as well as Russia and the united states, 
comprising a total of 44,260 individuals.
Main findings and 
limitations
Willingness to take a COVID-19 vaccine is 
considerably higher in the LMICs in our sample 
than in the united states and Russia. the personal 
protective benefit of vaccination is the most 
frequently cited reason for vaccine acceptance. 
Concern about side effects is the most commonly 
cited reason for vaccine hesitancy. Health workers 
are considered the most trusted sources of guidance 
about COVID-19 vaccine choices. One limitation 
of our study is that our data are not representative 
of all LMICs, and some individual samples are 
not nationally representative. However, our main 
findings—of high COVID-19 vaccine acceptance 
in our LMIC samples relative to the united states 
and Russia—are consistent across samples and 
specifications.
Policy implications Although global vaccine distribution has skewed 
heavily toward higher-income countries so far, 
the high levels of vaccine acceptance we identify 
suggest that prioritizing distribution to LMICs 
may be an efficient way to achieve immunity on 
a global scale and prevent novel variants from 
emerging. Vaccination campaigns should focus on 
converting positive intentions into uptake, which 
may require investment in local supply chains and 
delivery. Engaging health workers to deliver vaccine 
information, leveraging pro-vaccine norms, and 
messaging focused on vaccine effectiveness and 
safety might be effective in addressing remaining 
hesitancy.
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significant at P < 0.01). Respondents under age 25 years and 
less-educated respondents are marginally more willing to take the 
vaccine than older and more educated respondents, respectively, but 
these differences are not statistically significant.
Supplementary Table 3 provides results disaggregated by demo-
graphic subgroups for individual studies. The average gender dif-
ferences in the aggregate LMIC analysis are driven by the Burkina 
Faso, Mozambique, Pakistan (survey 1), Rwanda and Sierra Leone 
(survey 1) samples. However, these gender differences in accep-
tance are less than 10 percentage points in each of these samples, in 
contrast to the larger gender gaps in acceptance we observe in the 
United States (17%) and Russia (16%).
Less-educated respondents expressed significantly higher accep-
tance in the Burkina Faso, Rwanda, Sierra Leone (survey 1) and 
Uganda (survey 2) samples, which represent the majority of studies 
from Sub-Saharan Africa. Notably, we observe the opposite pattern 
in the India, Pakistan survey 1 and Pakistan survey 2 samples. In all 
three of these studies, acceptance is greater among more educated 
respondents, although this difference is not statistically significant 
in the India sample. Education is also a positive and significant pre-
dictor of acceptance in the United States.
We find mixed evidence across studies with respect to the 
relationship between age and COVID-19 vaccine acceptance. In 
India and Nigeria, respondents younger than 25 years of age are 
significantly less willing to take the vaccine relative to adults who 
are 25–54 years old, while in Mozambique, Pakistan survey 1 and 
Rwanda, those under 25 years are significantly more willing. In 
Mozambique and Rwanda, respondents under 25 years are also 
significantly more accepting compared to those 55 years and over; 
however, the difference between these age groups is not statistically 
significant in other LMIC samples. In the United States and Russia, 
older respondents are consistently more accepting than younger 
respondents.
To better understand the reasoning behind vaccine acceptance, 
we asked those who were willing to take the vaccine why they would 
take it. We summarize these results in Supplementary Table 4, with 
additional details in Supplementary Table 5. The reason most com-
monly given for vaccine acceptance across samples is personal pro-
tection against COVID-19 infection. The average across the LMIC 
samples is 91% (CI 86–96%), with a median of 92.5% and a range of 
22 pp. In every individual study, including the United States (94%, 
CI 92–95%) and Russia (76%, CI 74–78%), this ranks as the most 
cited reason. In distant second place in the aggregate LMIC analysis 
is family protection, with an average of 36% (CI 28–43%), a median 
of 34.5% and a range of 39 pp. In comparison to protecting one-
self and one’s family, protecting one’s community does not feature 
prominently among stated reasons for acceptance. These reasons 
do not vary substantially by age group, as shown in Supplementary 
Table 6.
Figure 2 summarizes the reasons given by respondents who said 
they were not willing to take a COVID-19 vaccine. The results from 
Fig. 2 are reproduced in Supplementary Table 7. Concern about side 
effects is the most frequently expressed reason for reluctance in our 
LMIC samples. This concern is particularly evident among samples 
from Sub-Saharan Africa. In Uganda survey 1 (85.1%, CI 80.7–
89.6%), Sierra Leone survey 2 (57.9%, CI 50.1–65.7%), Sierra Leone 
survey 1 (53.5%, CI 47.1–59.9%) and Uganda survey 2 (47.3%, CI 
42.2–52.5%), a sizable percentage of respondents unwilling to take 
the vaccine cited worries about side effects. Respondents in Russia 
(36.8%, CI 35.2–38.4%) and even more in the United States (79.3%, 
CI 74.6–84%) frequently report this concern.
The Uganda survey 2 (31%, CI 25.9–36.2%), Mozambique 
(29.7%, CI 18.6–40.8%) and Pakistan survey 1 (26%, CI 18–34%) 
study samples show relatively high levels of skepticism about vac-
cine effectiveness among hesitant respondents. This is also true in 
Russia (29.6%, CI 28.1–31.1%) and the United States (46.8%, CI 
41–52.6%). In addition, some hesitant respondents cite lack of con-
cern about COVID-19 infection as a reason not to be vaccinated. 
This answer is particularly common in the United States (39.3%, 
CI 33.5–45%), Pakistan survey 1 (29.4%, CI 20.9–37.9%) and Nepal 
(20.4%, CI 6.7–34.1%) studies.
In Fig. 3 we report respondents’ most trusted source of guidance 
when deciding whether to take a COVID-19 vaccine. The results 
from Fig. 3 are reproduced in Supplementary Table 8.
We find striking consistency across studies. In all samples except 
Rwanda, including those from Russia and the United States, respon-
dents identify the health system as the most trustworthy source to 
help them decide whether to take the COVID-19 vaccine. The aver-
age across LMIC samples is 48.1% (CI 31.6–64.5%), with a median 
of 44.1% and range of 66.3 pp. Respondents in Sierra Leone survey 2 
Table 2 | Vaccination beliefs and coverage for the countries studied








Percent of parents with 
any child that was ever 
vaccinated
Burkina Faso 87 72 95 98 95 88 97
Colombia 83 84 99 89 92 95 95
India 96 97 98 92 94 95 92
Mozambique 87 93 98 94 93 87 95
Nepal 89 93 99 96 96 92 95
Nigeria 82 92 96 67 65 54 95
Pakistan 91 92 95 88 86 75 94
Rwanda 99 97 99 98 99 96 100
sierra Leone 95 95 99 86 95 93 97
uganda 82 87 98 88 99 87 98
Russia 67 48 80 96 97 98 96
united states 85 73 87 – 97 90 95
the table presents an overview of vaccination beliefs and incidence across countries in our sample. Columns 2–4 and 8 use data from the Wellcome global Monitor 201814. Column 8 shows the percentage 
of respondents who are parents and report having had any of their children ever vaccinated. Columns 2–4 show the percentage of all respondents that either strongly agree or somewhat agree with the 
statement above each column. All percentages are obtained using national weights. Columns 5–7 use data from the World Health Organization on vaccine incidence15. Columns 5–7 report the percentage of 
infants per country receiving the vaccine indicated in each column.
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(89.3%, CI 87.2–91.5%), Nigeria (58%, CI 55.7–60.2%) and Burkina 
Faso (51.6%, CI 48.5– 54.8%) cited health workers most often. Sierra 
Leone has the highest trust in health workers and the Ministry of 
Health, potentially reflecting investments in public health following 
the 2014–2015 Ebola epidemic27.
In Colombia (36.6%, CI 33.5–39.7%), Nepal (35.6%, CI 32.9–
38.3%), Russia (28.1%, CI 26.8–29.3%) and Burkina Faso (18.4%, 
CI 16–20.9%), the next most cited sources are family and friends. 
Across the pooled samples, women appear to be three percentage 
points more likely to rely on family and friends than male respon-
dents, though this difference is not statistically significant (Extended 
Data Fig. 1).
By contrast, in Sierra Leone survey 1 (32.5%, CI 29.7–35.4%), 
Uganda survey 2 (32.4%, CI 29.9–35%), United States (29.7%, CI 
27–32.3%) and Nigeria (18%, CI 16.2–19.8%), the government is 
the second most frequently cited. Religious leaders and celebrities 
are not seen as the top sources of guidance by many respondents 
in any sample other than Nepal, where many respondents say they 
most trust famous people (16.1%, CI 13.3–18.9%).
Finally, we highlight two idiosyncratic, yet frequently men-
tioned, trusted sources of information in deciding whether to take 
a COVID-19 vaccine. In Rwanda, 34% of respondents would most 
trust ‘themselves’ for guidance, the most frequent response in this 
sample. In the United States, 14% of respondents cited Joe Biden, 
then president-elect and therefore excluded from the ‘government’ 
category, as their most trusted source.
Discussion
The current study contributes to the emerging picture of global vac-
cine acceptance by focusing on COVID-19 vaccine attitudes in a 
set of low-income and lower-middle-income countries. Our find-
ings show variable but broadly high levels of prospective COVID-
19 vaccine acceptance across the LMICs we study, using data from 
20,176 respondents in 13 studies in 10 LMICs in Africa, South Asia 
and Latin America. Acceptance across these LMIC samples aver-
aged 80.3%, ranging between 66.5% and 96.6% with a median of 
78%. The two benchmark countries, Russia and the United States, 
demonstrate lower COVID-19 vaccine acceptance, consistent with 
Table 3 | Summary of study sampling protocols
Study Date Geographic scope Sampling methodology Survey 
modality
Weights
Burkina Faso 15 October to 4 
December 2020
National RDD Phone Yes
Colombia 15–25 August 
2020
National RDD Phone Yes




Representative sample of slum dwellers living in the vicinity 
of a community toilet and located in uttar Pradesh
Phone Yes




(1) Random sample in urban and peri-urban markets stratified 
by gender and type of establishment in Maputo; (2) random 
sample representative of communities in the Cabo Delgado, 
stratified on urban, semi-urban and rural areas
Phone No




Random sample of poor households from randomly selected 
villages in Kanchanpur
Phone Yes




(1) Random sample of individuals in Kaduna; (2) sample of 
phone numbers from a phone list of Kaduna state residents
Phone No




Random sample of individuals in administrative police units in 
two districts of Punjab
Phone Yes




RDD on a random sample of all numerically possible mobile 
phone numbers in the region of Punjab
Phone No




sample recruited from the Russian online survey company 
OMI (Online Market Intelligence); sampling was targeted at 
having a minimum of 150 respondents per region, as well as 
representation of age, gender and education group
Online Yes
Rwanda 22 October to 15 
November 2020
National RDD Phone Yes
sierra Leone 1 2–19 October 
2020
National RDD Phone Yes
sierra Leone 2 7 October 2020 to 
20 January 2021
National Random sample of households in 195 rural towns across all 14 
districts of sierra Leone
Phone No




sample of women in households from semi-rural and rural 
villages across 13 districts in uganda, selected according to 
the likelihood of having children
Phone No




Random sample of households in Kampala Phone No
united states 4–5 December 
2020
National Nationwide sample of adult internet users recruited through 
the market research firm Lucid
Online Yes
RDD, random digit dialing.
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lower pre-pandemic childhood vaccine confidence in these coun-
tries, as shown in Table 2.
Many metrics and indices measure vaccine acceptance and 
hesitancy globally28–31. Our surveys use measures employed in 
other COVID-19 vaccine acceptance studies3,6–11 and that are rec-
ommended by the WHO Data for Action guidance32, allowing for 
meaningful cross-study and cross-country comparisons. We mea-
sure trust in sources of information about COVID-19 vaccination 
using a measure similar to that used in the Vaccine Confidence 
Index (VCI), a widely used survey tool4.
Consistent with other studies, we find higher average vaccine 
acceptance among men than women3,7–10. In contrast to studies 
focused primarily on higher-income countries, we find no consis-
tently significant differences with respect to age7,9 or education in 
our LMIC samples.
A key contribution of our study relative to the existing literature 
is its focus on the reasons why respondents express intentions to 
take (or refuse) a COVID-19 vaccine. Other work has highlighted 
appeals to altruistic behavior or other prosocial motivations to pro-
mote vaccine acceptance33, yet we find that the potential risks and 
benefits to personal well-being feature much more prominently 
in our respondents’ reasoning, suggesting that appeals about per-
sonal protection could be more effective in the countries under 
study here.
The most commonly stated reason for vaccine refusal is concern 
about safety (side effects). The vast majority (86%) of our surveys 
were conducted as reports from phase 2 and 3 clinical trial data 
were emerging for the earliest commercially available vaccines, 
but prior to the first Emergency Use Authorization of any vaccine 
(the BNT162b vaccine was approved by the United States on 11 
December 2020). Early trial data showed that severe adverse effects 
were extremely rare34–39, occurring in fewer than 10% of people in 
clinical trials40. Our respondents’ concern about side effects could 
reflect the rapid pace of vaccine development41 and the limited 
All By gender By education By age
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Fig. 1 | Acceptance rates, overall and by respondent characteristics. Average acceptance of the COVID-19 vaccine across studies and subgroups within 
studies. For each study, we summarize sampling information in parentheses in the following way: (1) we indicate whether the geographic coverage of the 
sample is national or subnational. If the coverage is subnational we provide further details; (2) we list the number of observations included in the study. In 
the plot, points represent the estimated percentage of individuals who would take the vaccine. ‘No’, ‘Don’t know’ and ‘Refuse’ are taken as a single reference 
category. Bars around each point indicate a 95% confidence interval for the estimate. the ‘All LMICs (national samples)’ row reports averages for just the 
LMIC samples with national-level geographic coverage. An estimate of average acceptance for all studies in LMICs (excluding the united states and Russia) 
is also shown in the ‘All LMICs’ row.
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information available about potential COVID-19 vaccine safety at 
the time of data collection. These concerns could also reflect wor-
ries about mild, yet common and transient side effects, such as 
fatigue, muscle pain, joint pain and headache.
Intensive media coverage of adverse events may exacerbate con-
cerns about side effects42. In particular, new information about rare 
but severe cases of thrombosis associated with the AstraZeneca 
vaccine that appeared after our data collection period could affect 
hesitancy levels. This is of particular relevance to LMICs, which 
are likely to rely on the AstraZeneca vaccine in their immunization 
campaigns through initiatives such as COVAX.
Concerns about vaccine efficacy, averaging 19.2% in the LMIC 
samples, may also reflect a lack of information about vaccines at the 
time of our surveys. However, we note that respondents in our samples 
rarely cited conspiracy theories about ulterior motives on the part of 
corporations, politicians or the pharmaceutical industry, despite atten-
tion given to fears about these issues in higher-income countries43.
Our study has several limitations, which we address here. First, 
our data are not representative of all LMICs. They instead repre-
sent a sample of studies in countries where our organizations could 
quickly and safely mobilize coordinated data collection. Second, 
samples from the countries we include here are not fully nationally 
representative. Phone surveys, although necessary during a global 
pandemic, do not include individuals who reside outside cover-
age areas, lack access to a cell phone or do not respond to calls. In 
addition, as shown in Table 3, several studies focus on subnational 
populations of interest from pre-existing studies to which questions 
about COVID-19 vaccination were added. Particular care should be 
taken in extrapolating these findings to national populations.
In spite of this variation in sample composition, our main find-
ings—of high COVID-19 vaccine acceptance in our LMIC samples 
relative to the United States and Russia—are remarkably consistent 
across studies. We conduct several robustness checks to probe the sen-
sitivity of our aggregate LMIC analysis to the inclusion of particular 
samples. First, as shown in Extended Data Fig. 2, we re-estimate aggre-
gate vaccine acceptance across our LMIC samples, successively drop-
ping one and two study samples at a time. Regardless of which samples 
are excluded, the average vaccine acceptance rate among LMIC sam-
ples remains consistent and considerably higher than in the United 
States and Russia, demonstrating that our results are not driven by the 
peculiarities of one or two studies. Second, we repeat the same analy-
sis excluding all samples that are subnational in scope, which yields a 
mean acceptance rate of 78.4% (CI 67.9–89%), as shown in the row 



























































Why would you not take the COVID-19 vaccine?
Estimate (%)
Fig. 2 | Reasons not to take the vaccine. the percentage of respondents mentioning reasons why they would not take the COVID-19 vaccine. In the plot, 
points represent the estimated percentage of individuals that would not take the vaccine or do not know if they would take the vaccine for each possible 
response option. Bars around each point indicate the 95% CI for the estimate. An estimated average for all studies in LMICs is also shown. the size of the 
points illustrates the number of observations in each response option. the India and Pakistan survey 2 studies are not included because they either did not 
include the question or were not properly harmonized with the other studies.
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The expressed intentions to take a COVID-19 vaccine that we 
document in our LMIC samples, if translated into behavior, would 
meet or exceed the current herd immunity threshold for COVID-
19 in many, but not all, countries (estimated to be between 70 and 
80%, based on the predominant variant in circulation in different 
countries)44–46. Reported intentions may, however, not always trans-
late into vaccine uptake47. The high salience of COVID-19 may have 
increased reported intentions. Conversely, reports about side effects 
and risks associated with expedited vaccine development may 
have increased hesitancy. The fast-moving pandemic and vaccine 
development context may change perceptions about vaccines by the 
time they are widely available in LMICs.
Indeed, previous research on vaccine hesitancy has emphasized 
how concerns that arise surrounding vaccination campaigns are 
often case- and context-specific48, making it difficult to predict 
exactly how COVID-19 vaccines will be received in any given setting. 
The lower COVID-19 vaccine acceptance rates we observe in Russia 
and the United States, for example, may reflect the politicization of 
this specific pandemic and of vaccine development49–52, in addition 
to generally greater vaccine skepticism.
Nonetheless, our findings suggest several concrete implications 
for policy relating to vaccine rollout in LMICs. First and fore-
most, we document high levels of COVID-19 vaccine acceptance 
in our LMIC samples compared to Russia and the United States. 
Although global vaccine distribution has skewed heavily toward 
higher-income countries so far3, our findings suggest that prioritiz-
ing distribution to LMICs is justified not only on equity grounds, 
but on the expectation of higher marginal returns in maximizing 
global coverage more quickly.
The high stated acceptance rates we document also imply that, once 
vaccine distribution to LMICs begins in earnest, interventions should 





































































































































































































































































Fig. 3 | Trusted sources respondents say they would trust most to help them decide whether to take the COVID-19 vaccine. Histograms of sources 
respondents say they would trust most to help them decide whether to take the COVID-19 vaccine. Respondents were only permitted to select one most 
trusted actor or institution. the India, Mozambique, Pakistan survey 1, Pakistan survey 2 and uganda survey 1 studies are not included because they either 
did not include the question or were not properly harmonized with the other studies.
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low-cost nudges may be effective in this regard. Two recent large-scale 
studies in the United States found that vaccination appointment 
reminder messages from healthcare providers increased influenza 
vaccine uptake53,54. Similar interventions have proven effective in 
increasing immunization in LMIC contexts. In Ghana and Kenya, 
vaccination reminders combined with small cash incentives increased 
childhood immunization coverage55,56. Cash and in-kind incentives 
programs were also effective in Nigeria and India57,58.
This recommendation is consistent with accepted frameworks, 
such as the WHO’s Behavioral and Social Drivers of vaccina-
tion (BeSD) model, which suggest leveraging favorable intentions 
through reminders and primes, and reducing access barriers when 
the vast majority of people intend to be vaccinated32,59. In particular, 
because COVID-19 vaccination may be more collectively than indi-
vidually optimal, ease of access is critical to achieving high cover-
age60. The availability of single-dose vaccines could be advantageous 
in settings with high vaccination demand but relatively low-capacity 
healthcare systems, as is the case in many LMICs.
Our findings also suggest directions for the design and delivery 
of messaging to address remaining COVID-19 vaccine hesitancy in 
the countries under study here. Persuasion campaigns may be par-
ticularly important in countries where acceptance rates are below 
herd immunity thresholds. We highlight three potential implica-
tions for messaging below, but urge policymakers and stakeholders 
to utilize country-specific results to develop further strategies that 
may work best in their particular context. We also echo calls for 
integrating rigorous impact evaluation of vaccine hesitancy inter-
ventions in all contexts, given limited evidence so far61.
First, our data strongly support the view that respondents from the 
included set of LMICs prefer to follow the guidance of practitioners 
with the most relevant knowledge and expertise. We find high levels 
of trust in health workers, which suggests that social and behavioral 
change communication strategies engaging local health workers may 
be particularly effective in combating remaining hesitancy50,62. Health 
workers have also been the first group to receive the COVID-19 vac-
cine and are therefore best positioned to share locally credible experi-
ences of vaccination63. Although celebrities were rarely identified as a 
most trustworthy source for COVID-19 advice in our study, celebrity 
endorsements have proven effective in other contexts and may com-
plement a strategy that primarily focuses on health workers64.
Second, our findings offer some guidance on the specific con-
tent of vaccine messaging that is likely to be most effective in per-
suading those who may be hesitant. Hesitant respondents were 
most concerned about side effects and vaccine efficacy. This sug-
gests that proactive messaging, initiated before large-scale vaccina-
tion campaign rollout, should highlight the high efficacy rates of 
the COVID-19 vaccines currently on the market in reducing or 
eliminating disease, hospitalizations and death, and communicate 
accurate information about potential side effects, including the rar-
ity of severe adverse events that may have contributed to hesitancy 
through widespread media coverage65,66.
Third, consistent with previous studies on COVID-19 vacci-
nation3,7–10, our study finds lower vaccine acceptance, on average, 
among women than men, suggesting that messaging strategies 
focusing on women may be important in addressing overall hesi-
tancy. Recent work in Latin America on COVID-19 vaccine mes-
saging found that the provision of basic information about the 
vaccines was particularly effective in persuading hesitant women67. 
More generally, countries may consider tailoring their messaging 
campaigns to address concerns held by more hesitant subpopula-
tions, which vary across our samples with respect to age, gender 
and education. Additional research is needed to identify and design 
effective messaging campaigns to overcome hesitancy among spe-
cific subpopulations in each setting61,65.
Finally, the high coverage rates of existing vaccines, coupled with 
respondents’ reliance on friends and family as information sources, 
suggest that the general pro-vaccination stance of many LMIC citi-
zens could be leveraged to increase uptake of COVID-19 vaccines as 
they become available. This might yield particularly strong results 
in Colombia and Nepal, where family members and friends are seen 
as an important source of advice when deciding whether to take 
a COVID-19 vaccine. Social learning strategies and norm-setting 
are powerful drivers of behavior in many related sectors. Social sig-
naling of positive attitudes towards vaccines may help shift social 
norms toward even greater immunization acceptance and uptake 
in the community at large68–70. As with messaging, policymakers 
should consider designing and evaluating social mobilization strat-
egies targeted toward more hesitant subgroups71.
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Methods
Study protocols. All studies analyzed in this Article were conducted via phone or 
online (United States and Russia) between 17 June 2020 and 18 January 2021. Table 
3 presents the geographic scope, sampling methodology and survey modality for 
each study.
Consent. All participants consented to participation in the research either verbally 
or via online forms (United States and Russia only).
Ethical approvals. Each of the individual studies independently obtained IRB 
approval. The Burkina Faso study was approved via IPA IRB protocol 15608 and 
the Burkina Faso Institutional Ethics Committee for Health Sciences Research 
approval A13-2020. The Colombia study was approved via IPA IRB protocol 
15582. The India study was approved via the London School of Economics (REC 
ref. 1132). The Mozambique study was approved by Universidade Nova de Lisboa. 
The Nepal study was approved via Yale University IRB protocol 2000025621. The 
Nigeria study was approved via the IRB at the University of Pennsylvania (protocol 
834548). Pakistan survey 1 was approved via Princeton University IRB protocol 
7250. Pakistan survey 2 was approved via Lahore University of Management 
Sciences IRB protocol LUMS-IRB/07012020SA. The Rwanda Research for Effective 
COVID-19 Responses (RECOVR) study was approved via IPA IRB protocol 15591, 
Rwanda National Institute for Scientific Research permit no. 0856/2020/10/NISR 
and Rwanda National Ethics Committee approval no. 16/RNEC/2020. The Russia 
study was approved via Columbia University IRB protocol IRB-AAAT4453. Sierra 
Leone survey 1 was approved via IPA IRB protocol 15592 and the Sierra Leone 
Ethics and Scientific Review Committee (no number provided, letter available 
upon request), and Sierra Leone survey 2 was approved via the Sierra Leone Ethics 
and Scientific Review Committee (SLERC 2904202) and Wageningen University 
(24062020). Uganda survey 1 was approved via Mildmay Uganda Research 
Ethics Committee (protocol no. 0109-2015). Uganda survey 2 was approved via 
IPA IRB protocol no. 15018, WZB Berlin Social Science Center Ethics Review 
Board protocol no. 2020/0/91, NYU Abu Dhabi IRB protocol no. HRPP-2020-64, 
MIT Committee on the Use of Humans as Experimental Subjects protocol no. 
2005000155 and the Mildmay Uganda Research Ethics Committee protocol no. 
0604-2019. The US study was approved via Cornell University IRB under protocol 
no. 2004009569.
Survey questions and sample construction. Survey data were collected between 
June 2020 and January 2021. Our main outcome measure was vaccine acceptance. 
Across studies, we asked respondents, ‘If a COVID-19 vaccine becomes available 
in [your country], would you take it?’. This measure aligns with widely reported 
COVID-19 vaccine acceptance measures3,6–11. If the respondent answered yes to 
this question, we followed up with the question, ‘Why would you take it? [the 
COVID-19 vaccine]’. If the respondent said they would not be willing to take 
the vaccine, we followed up with the question, ‘Why would you not take it? [the 
COVID-19 vaccine]’. Finally, regardless of their expressed willingness to take the 
vaccine, we asked about groups and institutions that would be most influential in 
their decision: ‘Which of the following people would you trust MOST to help you 
decide whether you would get a COVID-19 vaccine, if one becomes available?’ 
following recent work on vaccine confidence4. To examine heterogeneity across 
demographic strata, we collected information about gender, age and education. 
Slight variations in question wording and answer options across studies are 
documented in Supplementary Tables 9–12.
The studies varied in terms of geographic scope, sampling methodology and 
survey modality. Seven were national or nearly national in scope. Studies from 
Burkina Faso, Colombia, Rwanda and Sierra Leone (survey 1) used nationally 
representative samples of active mobile phone numbers reached through random 
digit dialing (RDD). Sierra Leone survey 2 was conducted by phone among a 
random sample of households in 195 rural towns across all 14 districts of the 
country. Studies in the United States and Russia were conducted online using quota 
samples obtained from private survey companies.
The remaining eight studies targeted subnational populations. One study 
from Pakistan (Pakistan survey 2) used RDD in Punjab Province. Respondents in 
Mozambique, Nigeria, Pakistan (Pakistan survey 1), Uganda (Uganda survey 1 and 
Uganda survey 2), India and Nepal were drawn from pre-existing studies to which 
COVID-19 vaccine questions were subsequently added. For example, Uganda 
survey 1 sampled female caregivers of households in rural and semi-rural villages 
as part of a large ongoing cluster randomized controlled trial implemented across 
13 districts.
Table 3 summarizes the dates of data collection, geographic scope, sampling 
methodologies and survey modalities of all 15 studies.
All surveys were conducted remotely to minimize in-person contact and 
comply with social distancing guidelines. Interviews were conducted by local 
staff in each country in the local language(s). Surveying by phone made rapid, 
large-scale data collection possible. In two samples, the United States and Russia, 
surveys were carried out via online polling. All surveys lasted ~15–40 min.
Taken together, we have data from 20,176 individuals from 10 LMICs and 
24,084 from the United States and Russia, for a total of 44,260 respondents. We 
report data missingness patterns in Supplementary Table 13.
Detailed study protocols. The Burkina Faso, Colombia, Rwanda and Sierra Leone 
survey 1 samples were drawn from the RECOVR studies implemented by IPA. 
The target population for these studies comprised all adults with mobile phone 
numbers in the country, based on national communications authority number 
allocation plans. The sampling frame consisted of all mobile phone numbers in the 
countries. Numbers were called via RDD, stratified by mobile network operator 
market share for a two-round panel survey. In Burkina Faso, the sample included 
977 respondents contacted in the second round of a panel of 1,383. In Colombia, 
the sample included 1,012 respondents contacted in the second round of a panel of 
1,507. In Rwanda, the sample included 1,355 respondents contacted in the second 
round of a panel of 1,480. In Sierra Leone survey 1, the sample included 1,070 
respondents contacted in the second round of a panel of 1,304. Post-stratification 
weights were computed to adjust for differential attrition between the first and 
second rounds of the RDD panel, weighting on gender, region and educational 
attainment.
The ‘India, Coping with COVID-19 in Slums’ subnational sample was drawn 
from research undertaken by the Nova School of Business and Economics, The 
Institute for Fiscal Studies, and the University of St Andrews. The target population 
was a random subset of slum populations in Lucknow and Kanpur, Uttar Pradesh, 
India. Socio-economic variables were only collected for a representative sample 
of the population relying on community toilets or open defecation to fulfill 
their sanitation needs. The study design was a randomized controlled trial, with 
complete census of households within 142 slums (carried out from September 
to December 2017) and a series of household and caretaker surveys, objective 
measurements, incentivized behavioral measurements and a structured community 
activity, collected for a subset of 100 slums between April 2018 and September 
2019. The catchment areas of community toilets were randomly allocated to two 
interventions. The first intervention aimed at community toilet improvements 
by offering caretakers the choice of a grant to be spent for improvements in the 
facility. Following the grant, caretakers were offered a large financial reward 
conditional on the cleanliness of the facility. The second intervention added to 
this community toilet improvement awareness creation through face-to-face 
information sessions, leaflets, monthly reminders using voice messages sent to 
mobile phones, and posters hung in the community toilets. A two-step sampling 
was applied: study households from the main study sample were first sampled, then 
households from the whole slum population were added. The baseline ran from 
June to July 2020, follow-up 1 ran from October to November 2020, and follow-up 
2 ran from 16 December 2020 to 18 January 2021. The sample size was 3,991 
households, with a mean of 28 households per cluster (142). Baseline non-response 
was 25%, and the attrition rate from baseline to follow-up (1 and 2) was 13%. The 
study included 1,277 randomly selected replacement households for follow-up (1 
and 2). Sampling weights are included.
The Mozambique subnational sample, implemented by the International 
Growth Center and the Nova School of Business and Economics, targeted 
microentrepreneurs in the urban markets of Maputo and household heads from 
the province of Cabo Delgado. The initial data were collected in person in two 
different studies. For microentrepreneurs in Maputo, the data were collected 
between October 2013 and April 2014 (baseline) and between July and November 
2015 (endline). For household heads in Cabo Delgado, the data were collected in 
person between August and September 2016 (baseline) and between August and 
September 2017 (endline). The first study was dedicated to analyzing the impacts 
of interventions targeting microentrepreneurs in urban markets on financial 
inclusion and literacy. The second study focused on the role of information to 
counteract the political resource curse after a substantial natural gas discovery. 
The first initial sample was selected by in-field random sampling in 23 urban and 
peri-urban markets in Maputo and Matola. Stratification was based on the gender 
of the respondent and on the type of establishment (stall versus store). The second 
initial sample was selected to be representative of 206 communities in the province 
of Cabo Delgado, randomly drawn from the list of all 421 polling locations in 
the sampling frame, stratified on urban, semi-urban and rural areas. The sample 
includes 554 microentrepreneurs from Maputo and 308 households from  
Cabo Delgado.
The Nepal Western Terai Panel Survey (WTPS) subnational sample was 
implemented by researchers from Yale University and the Yale Research Initiative 
on Innovation and Scale (Y-RISE). Its target population was rural households 
in the districts of Kailali and Kanchanpur. Initial baseline data was collected in 
person in July 2019, and five rounds of phone survey data were collected between 
12 August 2019 and 4 January 2020. The phone survey sample included 2,636 
rural households in the districts of Kailali and Kanchanpur that represent the set 
of households that responded to phone surveys from an original sample of 2,935 
households. This sample was constructed by randomly sampling 33 wards from 15 
of the 20 subdistricts in Kailali and Kanchanpur and selecting a random 97 villages 
from within those wards. At the time of baseline data collection in July 2019, 7 
of these 97 villages were dropped from the sample due to flooding. Households 
belong to the bottom half of the wealth distribution in these villages, as estimated 
by a participatory wealth-ranking exercise with members of the village. The sample 
included in this study comprised 1,392 households.
The Nigeria subnational sample was implemented by researchers from WZB 
Berlin Social Science Center and the University of Illinois Chicago. The target 
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population included Christian and Muslim men and women, aged 18 years and 
above, living in Kaduna State, Nigeria. Initial data were collected from a subset of 
the sample in December 2019 (in person survey) and July to August 2020 (phone 
survey) as part of an experiment testing the effects of a brief radio program on 
inter-religious animus. A random walk procedure and random sampling were used 
within households to recruit a representative sample of adults in Kaduna town. The 
rest of the sample was recruited for the study in August 2020 by purchasing phone 
lists of residents of Kaduna State. The subset of the sample in the radio study was 
randomly assigned to listen to a brief radio program on one of the following topics: 
(1) an inter-religious storyline, (2) an intra-religious storyline and (3) a message 
about maintaining safe health practices. All respondents in the sample participated 
in a study examining the effect of viewing an inter-religious storyline unfolding 
over a full season of a popular TV drama, Dadin Kowa. The season aired from 
August to October 2020. A third of the sample were encouraged to watch Dadin 
Kowa, a third were encouraged to watch the TV station Africa Magic Hausa at the 
same time Dadin Kowa aired, and a third were in the treatment-as-usual group. All 
participants received a weekly incentivized SMS quiz from August to October 2020. 
The survey from which the data were drawn is not primarily about COVID-19, but 
was designed as an endline survey to follow the TV drama intervention described 
above. The goal of the COVID-19 survey was to measure a range of attitudinal 
outcomes related to Christian–Muslim relations (including prejudice, intergroup 
threat perceptions, dehumanization and support for the use of violence, among 
others). We included nine of the standardized COVID-19 vaccine-related questions 
collected specifically for this vaccine acceptance study in the final module of 
the endline survey. A total of 950 respondents in the sample were recruited in 
person through a random sampling procedure in the Kaduna metropolitan area 
(pre-COVID). The remaining 1,700 respondents were recruited into the study 
over the phone from lists of phone numbers of Kaduna State residents that were 
purchased from a private vendor. All 1,834 individuals who completed the endline 
survey were included.
The Pakistan survey 1—the Sheikhupura Police Study Sample—was 
implemented by the Institute of Development and Economic Alternatives, Lahore 
University of Management Science, London School of Economics and Princeton 
University. The target population was a representative sample of adults from 108 
of 151 police beats in Sheikhupura and Nankana districts of Punjab Province. 
The survey involved calls to all households in the stratified random sample for 
the policing study midline survey. The sampling frame included households in 
Sheikhupura and Nankana districts, and the sample comprised 1,473 respondents. 
Post-stratification weights were computed to adjust for the sampling process, 
which involved stratifying first on 27 police stations, then within each police 
station on beats, then probability proportional to size (PPS) sampling within beats 
using Asiapop population data.
The Pakistan Economic Vulnerability Assessment (EVA) subnational sample 
(Pakistan survey 2) was implemented by Lahore University of Management 
Studies and targeted all possible mobile phone numbers in the province of Punjab 
generated based on the local mobile phone number structure in Pakistan. The 
survey involved making calls to individuals in Punjab based on RDD. The sample 
included 1,492 respondents.
The Russian Federation, Research on COVID-19 in Russia’s Regions 
(RoCiRR) subnational sample was implemented by the International Center for 
the Study of Institutions and Development (HSE University, Moscow, Russia) 
and the Economics Department of Ghent University and Columbia University. 
The target population was adult internet users who resided in one of 61 federal 
subjects (federal cities, oblasts, republics, krais and autonomous okrug) of Russia. 
The regions included in the study were the following republics (Bashkortostan, 
Karelia, Komi, Mariy El, Mordovia, Tatarstan, Udmurtia, Chuvashia), krais (Altai, 
Krasnodarsky, Krasnoyarsky, Permsky, Primorsky, Stavropolsky, Khabarovsky), 
oblasts (Arkhangelsk, Astrakhan, Belgorod, Bryansk, Vladimir, Volgograd, 
Vologda, Voronezh, Ivanovo, Irkutsk, Kaliningrad, Kaluga, Kemerovo, Kirov, 
Kostroma, Kurgan, Kursk, Leningrad, Lipetsk, Moscow, Murmansk, Nizhny 
Novgorod, Novgorod, Novosibirsk, Omsk, Orenburg, Orel, Pskov, Penza, Rostov, 
Ryazan, Samara, Saratov, Sverdlovsk, Smolensk, Tambov, Tver, Tomsk, Tula, 
Tyumen, Ulyanovsk, Chelyabinsk, Yaroslavl), as well as Moscow, Saint Petersburg 
and Khanty-Mansiysk Autonomous Okrug—Ugra. The remaining 24 federal 
subjects were excluded from the study due to the inability to enroll a sufficient 
sample size with the desired characteristics (sample size, age, gender and education 
group composition) and because they accounted for less than 14% of the total 
adult population of Russia. The study was designed to measure the impact of 
pandemics on Russians, mostly those who live in cities with more than 100,000 
residents. It contained a number of questions on personal experience, norms and 
values, trust in government institutions, provision of social services and mass 
media use. The region and geolocality of every respondent were recorded. In total, 
25,558 respondents received the module on vaccine acceptance. The sample was 
enrolled from the pool of Russian online survey company OMI (Online Market 
Intelligence). The sampling was specifically targeted at having a minimum of 150 
respondents in each of the 61 regions, including respondents from all the main 
age and gender groups within each region. Respondents were also selected so 
that at least 40% of respondents did not have higher education, in accordance 
with higher education rates in Russia. Of 25,558 recruited respondents, 22,125 
completed the survey. Among the 22,125 respondents who completed the survey, 
20,821 were enrolled from the general pull of the survey company respondents, 
while the remaining 1,304 respondents were enrolled among residents of cities 
with populations below 100,000 and rural areas. Post-stratification weights were 
computed to match marginal distributions of age, gender and education among the 
adult population of Russia with target proportions coming from the 2019 Yearbook 
and 2015 Microcensus released by the Russian Federal Bureau of National Statistics 
(Rosstat).
The Sierra Leone Rural Electrification (SLRE) project sample (Sierra Leone 
survey 2) included towns that were candidates for rural electrification. This 
nationwide sample was implemented by the International Growth Centre (IGC), 
Wageningen University & Research, Yale Research Initiative on Innovation and 
Scale (Y-RISE), WZB Berlin Social Science Center and Columbia University. The 
study included households in 195 rural towns across all 14 districts of Sierra Leone. 
Of these, 97 villages were selected to benefit from an electrification program. 
For the original study, initial baseline data were collected during late 2019 and 
early 2020 as part of a study to assess the impact of rural electrification in rural 
towns in Sierra Leone. The Government of Sierra Leone (GoSL) in collaboration 
with the United Nations Office for Project Services (UNOPS) and international 
donors was implementing the Rural Renewable Energy Project (RREP). In its first 
wave, during 2017, the project provided stand-alone solar photovoltaic powered 
mini-grids to 54 communities across the country. Construction of mini-grids 
in 43 additional towns is ongoing. In RREP communities, engineers construct 
6- to 36-kW power mini-grids that provide reliable power year-round. Electricity 
is free for schools and clinics. Residential and commercial users can acquire 
connections from commercial operators. Household data were collected in 195 
towns across all 12 districts of Sierra Leone. The GoSL selected 97 towns with 
(planned) mini-grids. We used propensity score matching to select 98 control 
communities. Within the communities, respondents were randomly selected 
from a census roster stratified by occupation status: farmers, business owners and 
other occupations (47%, 47% and 7%). In each village, the intended sample was 43 
households (20 farmers, 20 businesses, 3 others). Data were collected during June 
to July (108 communities) and November to December 2019 (87 communities). If a 
household on the sampling list was not available on the village visit day, a randomly 
sampled list of replacement households were available to survey. The replacement 
household would be the same occupation as the sampled household would have 
been to maintain the sample ratio of 20-20-3 in each community. The goal of the 
COVID-19 survey was to assess households’ degree of economic vulnerability in 
the face of the COVID-19 pandemic. The COVID-19 survey data comprised 2,110 
respondents from 186 towns from the original baseline survey. Phone surveys 
were attempted to all 195 rural communities from the baseline survey. The total 
baseline household sample comprised 7,047 respondents. We recontacted all 
baseline respondents that listed a phone number (4,594 respondents) and obtained 
informed consent for the phone survey. We implemented several waves of the 
phone survey, recontacting a respondent about every month. In wave 7, we added 
questions related to vaccine acceptability. Data collection took place between 7 
October 2020 and 20 January 2021, with 2,110 respondents in 186 towns, for a 
tracking rate of 46%.
The Uganda survey 1 subnational sample was implemented by the 
International Growth Center, Trinity College Dublin, Stockholm School of 
Economics and Misum, Institute for International Economic Studies, Stockholm 
University. The target population was women from semi-rural and rural villages 
across 13 districts in Uganda (Iganga, Kayunga, Mbale, Mityana, Apac, Dokolo, 
Gulu, Adjumani, Koboko, Maracha, Nebbi, Soroti and Kumi). For the original 
study, initial baseline data were collected in 2016 as part of a large cluster 
randomized controlled trial, with the aim of selecting households likely to have 
children during the study period. Four criteria for selection were thus used (in 
descending order of importance): the household has a woman that is currently 
pregnant, is aged 16–30 years, has a young child less than 3 years of age, and/or is 
married (formally or informally). In each household, the respondent was chosen as 
the female household head or the primary female healthcare giver of the household 
if the household head could not be found. The COVID-19 survey data were 
collected through multiple rounds of phone surveys. The variable measuring age 
was constructed by approximation, using the baseline data from 2016 and adding 
four years to the 2016 measure. When the baseline respondent was replaced, the 
initial age information was deleted. Households were selected within 500 clusters 
(the village of the household). Out of 2,743 respondents, 1,752 were included, 
provided that they answered the main question about vaccine uptake.
The Uganda survey 2 subnational sample was implemented by WZB Berlin 
Social Science Center and Columbia University, NYU Abu Dhabi and IPA. The 
target population was all residents of Kampala who were Ugandan citizens, above 
the age of 18 years and agreed in principle to attend a short citizen consultative 
meeting. For the original study, baseline data were collected between July and 
October 2019 for an intervention that randomized citizen attendance to a set of 
188 consultative meetings organized across Kampala. The meetings were organized 
to collect citizen preferences for the design of a forthcoming municipal citizen 
charter. The study also aimed to assess patterns of political inequality in meeting 
participation, dynamics and outcomes, as well as to study the subsequent effects 
on prosociality of being incorporated in this participatory process. One-third of 
the sample was randomly allocated as control and two-thirds of respondents were 
invited to attend a consultative meeting. The consultations took place between 
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November 2019 and February 2020 across Kampala divisions. The intervention 
consisted of attendance at the consultative meeting organized a few months after 
baseline data collection. A further randomization allocated half of the invited 
participants to a meeting moderated by a local bureaucrat, while the remaining 
ones attended a meeting moderated by a neutral discussion leader. The COVID-
19 survey sample comprised the 2,189 respondents to the baseline who were 
selected on the basis of their residence in the city. Having received permission to 
recontact these individuals, we coordinated a three-wave panel throughout the 
summer and fall of 2020, with respondents contacted via phone. The goal was to 
assess households’ degree of economic vulnerability in the face of the COVID-19 
pandemic and respondents’ evaluations of the performance of political actors 
in tackling the pandemic. The 2,189 respondents to the baseline were randomly 
selected from a sampling frame of all buildings in Kampala for which information 
about their geographical coordinates was available. After randomly selecting a 
set of candidate structures, interviewers sampled respondents from the subset of 
structures that were residential. Of the 2,189 respondents that we aimed to contact, 
we were able to reach 1,333 in wave 1, 1,289 in wave 2 and 1,366 in wave 3. Wave 3 
contained the COVID-19 vaccine module presented in this analysis.
The United States nationwide sample was implemented by WZB Berlin 
Social Science Center, Cornell University and Tufts University. The target 
population was a nationwide sample of adult internet users recruited through the 
market research firm Lucid. This survey was part of a panel study on attitudes 
toward COVID-19 technologies and public health surveillance. The Lucid 
Marketplace is an automated marketplace that connects researchers with willing 
online research participants. Lucid partners with a network of companies that 
maintain relationships with research participants by engaging them with research 
opportunities. Although Lucid does not provide probability samples of the US 
adult population, its quota samples approximate the marginal distributions of key 
demographic characteristics. Recent validation exercises have found that Lucid 
samples approximate nationally representative samples in terms of demographic 
characteristics and survey experiment effects72. The sample includes 1,959 
individual online surveys. In the main question regarding intention to take the 
vaccine, ~10% of respondents (184) did not answer. Post-stratification weights 
were computed to match marginal population distributions of income, age, 
education, gender, race and region among the US adult population, with target 
proportions based on the 2018 American Community Survey.
COVID-19 case history for countries included in the study. In the following we 
detail the COVID-19 case history for each country included in our study, based 
on data reported in the Johns Hopkins University Center for Systems Science and 
Engineering (JHU CSSE) database73.
In Burkina Faso, the first confirmed case of COVID-19 was recorded 9 March 
2020. As of 15 October 2020 (the first date of the survey round containing the 
questions used in this study), 2,335 confirmed cases and 65 COVID-19 deaths had 
been reported in the country.
In Colombia, the first confirmed case of COVID-19 was recorded 6 March 
2020. As of 15 August 2020 (the first date of the survey round containing the 
questions used in this study), 456,689 confirmed cases and 14,810 COVID-19 
deaths had been reported in the country.
In India, the first confirmed case of COVID-19 was recorded 30 January 2020. 
As of 17 June 2020 (the first date of the survey round containing the questions used 
in this study), 366,946 confirmed cases and 12,237 COVID-19 deaths had been 
reported in the country.
In Mozambique, the first confirmed case of COVID-19 was recorded 22 March 
2020. As of 30 October 2020 (the first date of the survey round containing the 
questions used in this study), 12,777 confirmed cases and 91 COVID-19 deaths 
had been reported in the country.
In Nepal, the first confirmed case of COVID-19 was recorded 23 January 2020. 
As of 1 December 2020 (the first date of the survey round containing the questions 
used in this study), 233,452 confirmed cases and 1,529 COVID-19 deaths had been 
reported in the country.
In Nigeria, the first confirmed case of COVID-19 was recorded 28 February 
2020. As of 18 November 2020 (the first date of the survey round containing the 
questions used in this study), 65,693 confirmed cases and 1,163 COVID-19 deaths 
had been reported in the country.
In Pakistan, the first confirmed case of COVID-19 was recorded 26 February 
2020. As of 24 July 2020 (the first date of the survey round containing the questions 
used in Pakistan survey 1), 271,887 confirmed cases and 5,787 COVID-19 deaths had 
been reported in the country. For Pakistan survey 2, by 2 September 2020, 297,014 
confirmed cases and 6,328 COVID-19 deaths had been reported in the country.
In Russia, the first confirmed case of COVID-19 was recorded 31 January 
2020. As of 6 November 2020 (the first date of the survey in this study), 1,720,063 
confirmed cases and 29,654 COVID-19 deaths had been reported in the country.
In Rwanda, the first confirmed case of COVID-19 was recorded 14 March 
2020. As of 22 October 2020 (the first date of the survey round containing the 
questions used in this study), 5,017 confirmed cases and 34 COVID-19 deaths had 
been reported in the country.
In Sierra Leone, the first confirmed case of COVID-19 was recorded 20 March 
2020. As of 2 October 2020 (the first date of the Sierra Leone Study 1 survey 
round containing the questions used in this study), 2,252 confirmed cases and 72 
COVID-19 deaths had been reported in the country. As of 7 October 2021 (the 
first date of the Sierra Leone Study 2 survey round containing the questions used 
in this study), 2,287 confirmed cases and 72 COVID-19 deaths had been reported 
in the country.
In Uganda, the first confirmed case of COVID-19 was recorded 21 March 2020. 
As of 21 September 2020 (the first date of the Uganda 1 survey round containing 
the questions used in this study), 6,468 confirmed cases and 63 COVID-19 deaths 
had been reported in the country. As of 23 November 2020 (the first date of 
the Uganda 2 survey round containing the questions used in this study), 18,165 
confirmed cases and 181 COVID-19 deaths had been reported in the country.
In the United States, the first confirmed case of COVID-19 was recorded 20 
January 2020. As of 4 December 2020 (the first date of the survey round containing 
the questions used in this study), 14,499,637 confirmed cases and 281,678 COVID-
19 deaths had been reported in the country.
Statistical analysis. Vaccine acceptance was defined as the percentage of 
respondents who answered ‘yes’ to the question, ‘If a COVID-19 vaccine becomes 
available in [country], would you take it?’. This was calculated combining all other 
answer options (‘No’, ‘Don’t know’ and ‘Refuse’) into a single reference category. 
We estimated the average acceptance for each individual sample via ordinary least 
squares (OLS) weighted by the respective study population weights and using 
robust standard errors clustered at the level of the sampling cluster.
In addition to study-level estimates, we combined data from all studies other 
than the United States and Russia to calculate an aggregate ‘All LMIC studies’ 
estimate. For these analyses, we estimated the average acceptance by OLS with 
weights for each study normalized such that the total weight given to observations 
was constant across studies. Robust standard errors for these analyses were 
clustered at the study level.
We note the core results would be virtually unchanged at 80.8% (74.5–87.1) 
rather than 80.3% (74.9–85.6) using countries rather than studies as groups in the 
pooled analysis, that is, if we set weights so that the sum of weights in each country 
(rather than in each study) sum to a constant and cluster standard errors at the 
country level (rather than the study level).
In this combined analysis, we also estimated the underlying heterogeneity of 
vaccine acceptance across studies using the between-studies variance estimator τ2 
from a random effects model.
We conducted subgroup analyses by gender, age and education level and 
reported differences between groups. For age, we selected cutoffs of below 
25 years, between 25 and 54 years, and 55 years and above, closely following the age 
breakdown proposed by recent work on COVID-19 vaccine acceptance11. However, 
the lower life expectancy (63 years on average)74 and younger-skewing populations 
(only 5% of the population is above 65 years old)75 of low-income countries, 
in particular, precluded further disaggregation at the upper end of the age 
distribution. For education, we divided the sample between respondents who had 
completed secondary school and those who had not. We defined these two groups 
to reflect broader schooling trends in LMICs, where out of every 100 students 
entering primary education, 61% complete lower secondary education76. The 
subgroup analyses estimates are calculated in exactly the same way as the overall 
acceptance rate—with weights again normalized to sum to a constant within each 
study—with the exception that the subsample used in the analysis is limited to 
those respondents fitting each demographic group.
We then investigated stated reasons for COVID-19 vaccine acceptance and 
hesitancy, and the types of sources respondents would trust most when making 
the decision about whether to take a COVID-19 vaccine. We report estimates of 
agreement with reasons for vaccine acceptance/hesitancy and trust in sources for 
individual studies and for the ‘All LMICs’ group, which includes all study samples 
except Russia and the United States. Estimates were calculated with the same 
procedure as above, varying only the quantity of interest; that is, one model is run 
for each reason why a respondent would (or would not) take the vaccine and each 
trusted source.
All statistical analyses, tables and figures were processed with the software R, 
version 4.0.4.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Individual participant data (de-identified) that underlie the results reported in this 
Article, analytic code and replication files are available (no end date) to anyone who 
wishes to access the data and use it for any purpose at https://github.com/wzb-ipi/
covid_vaccines_nmed. A replication exercise is available at https://wzb-ipi.github.
io/covid_vaccines_nmed/.
Code availability
All code has been deposited into the publicly available GitHub repository at https://
github.com/wzb-ipi/covid_vaccines_nmed. The code and output for all analyses 
can be easily inspected at https://wzb-ipi.github.io/covid_vaccines_nmed/.
NATuRE MEDICINE | www.nature.com/naturemedicine
Articles NATURE MEDICINE
References
 72. Coppock, A. & McClellan, O. A. Validating the demographic, political, 
psychological and experimental results obtained from a new source of online 
survey respondents. Res. Politics 6, 2053168018822174 (2019).
 73. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track 
COVID-19 in real time. Lancet Infect. Dis. 20, 533–534 (2020).
 74. World development indicators: life expectancy at birth, total (years)—low & 
middle income, low income countries (World Bank, 2018); https://data.
worldbank.org/indicator/SP.DYN.LE00.IN?locations=XO-XM
 75. World Bank staff estimates based on age/sex distributions of United Nations 
Population Division’s World Population Prospects: 2019 revision, population 
ages 65 and above (% of total population)—Sub-Saharan Africa (World Bank, 
2019); https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS?locations=ZG 
(2019).
 76. World development report 2018: learning to realize education’s promise 
(World Bank, 2017).
Acknowledgements
This work would not have been possible without the hard work and ingenuity of many. 
For valuable contributions to data collection during the challenging context of the global 
pandemic, we would like to thank the following people. Burkina Faso: IPA Burkina 
Faso staff in Ouagadougou for their support of the RECOVR (Research for Effective 
Covid Response) survey from which the questions used in this study were drawn. 
Colombia: IPA Colombia staff in Bogotá for their support of the RECOVR survey from 
which the questions used in this study were drawn. India: P. Sen (Country Director), 
K. Das (Program Policy Manager) and B. Mohanty (Country Economist) at IGC India 
and Morsel Research and Development’s field team. Mozambique: F. Mendonça and 
S. Paiva from NOVAFRICA Mozambique office. Nepal: field staff at the Centre for 
the Study of Labour and Mobility (CESLAM) in Kathmandu. Nigeria: S. Fayomi and 
A. Kumar at the Busara Center for Behavioral Economics and S. Ryan (University of 
Illinois at Chicago) for research assistance. Pakistan survey 1: staff at the Institute for 
Development and Economic Alternatives (IDEAS) in Lahore for their contributions 
to the Sheikhupura police study sample from which the questions used in the Pakistan 
survey 1 study were drawn. Pakistan survey 2: staff of the internal survey firm at the 
Centre for Economic Research Pakistan (CERP) for their contributions to the Economic 
Vulnerability Assessment (EVA) project from which the questions used in the Pakistan 
survey 2 study were drawn. Rwanda: IPA Rwanda staff in Kigali for their support of 
the RECOVR survey from which the questions used in this study were drawn. Russia: 
staff at Online Market Intelligence Survey Agency, Kirill Chmel (HSE University) and 
Vladimir Zabolotsky (HSE University and University of Bologna) for their intellectual 
contributions and research assistance. Sierra Leone survey 1: IPA Sierra Leone staff in 
Freetown for their support of the RECOVR survey from which the questions used in 
this study were drawn. Sierra Leone survey 2: J. Nabieu (Field Supervisor), M. Flee (Field 
Supervisor), H. Kai, M. Lamin (Field Supervisor) and all enumerators at IGC Sierra 
Leone Freetown office and Wageningen University’s Project ‘Tracking the Economic 
Consequences of COVID-19 in Sierra Leone’. Uganda survey 1: staff at IPA Uganda for 
their intellectual contributions, research assistance and support throughout the study. 
Uganda survey 2: Co-PIs Ana Garcia Hernandez, P. Kiwanuka-Mukiibi, L. Rosenzweig, 
L. Tsai and E. Atuhumuza and the team of survey enumerators and support staff at 
IPA Uganda. United States: staff at Lucid (survey firm) for distributing the survey and 
providing the online survey sample. IGC thanks the resident country teams in Sierra 
Leone, Uganda, Pakistan and Mozambique for their continued guidance, coordination 
of activities with researchers and direct engagement and dissemination activities with 
national policymakers: H. McLeod (Country Director) and A. Bakarr Kamara (Country 
Economist) at IGC Sierra Leone. R. Newfarmer (Country Director), P. Manwaring 
(Country Economist) and J. Rauschendorfer (Country Economist) at IGC—Uganda. 
I. Nabi (Country Director), H. Shaikh (Country Economist) and U. Naeem (Country 
Economist) at IGC—Pakistan. C. Frischtak (Country Director) and E. Daniel (Country 
Economist) at IGC Mozambique. IPA thanks staff from its global offices for their 
research assistance and support throughout the RECOVR survey. At IPA New York 
and Washington, DC, M. Rosenbaum and S. Henderson provided research support. 
NOVAFRICA thanks C. Batista (NOVA SBE), S. Sequeira (LSE) and I. Vilela (Royal 
Holloway, University of London and NOVAFRICA) for their intellectual contributions. 
Funding was provided by Beyond Conflict, Bill and Melinda Gates Foundation, 
Columbia University, Givewell.org, Ghent University, HSE University Basic Research 
Program, International Growth Centre, Jameel Poverty Action Lab Crime and Violence 
Initiative, London School of Economics and Political Science, Mulago Foundation, 
NOVAFRICA at the Nova School of Business and Economics, NYU Abu Dhabi, Energy 
for Economic Growth (EEG) programme led by Oxford Policy Management, funded by 
UK Aid, Princeton University, Social Science Research Council, Trinity College Dublin 
COVID19 Response Funding, UK Aid, UKRI GCRF/Newton Fund, United Nations 
Office for Project Services, Weiss Family Fund, WZB Berlin Social Science Center, Yale 
Institute for Global Health, Yale Macmillan Center and anonymous donors to IPA and 
Y-RISE.
Author contributions
J.S.S.A., S.S.W., N.F.M., A.S., N.M., G.S., M.V. and A.A.M. are co-first authors. D.K., 
M.C., M.T., M.H., A.M.M. and S.B.O. are co-last authors. A.M.M. and S.B.O. are the 
corresponding authors. D.K., A.M.M., M.T., N.F.M., M.C. and M.V. conceived the study 
and provided overall guidance. S. Aboutajdine and N.F.M. led the literature search, with 
input from A.S., N.M., S.S.W., A.M.M., A.A.M. and J.S.S.A. S.S.W., N.F.M., A.S., N.M., 
M.V., G.S., A.A., S. Asad, B.A., A.B., E.B., C.M.B., A.C., E.C., M.F., A.G., A. Kamwesgiye, 
S. Kreps, R.L., M.B.N., M.R.P., J.A.Q., J.N.S., J.S., P.C.V., M.C., S. Asad, A.C., A.Z.F., A.H., 
M.C., M.T., M.H., C.V., L.B.W., B. Zhang and B. Zafar oversaw data collection as part of 
other research efforts. O.A., D.A., M. Atyera, M. Awasthi, M.R.C.G., A.C., F.C., G.E.A., 
M.L.G.S., S.J., S. Kallon, A. Kamwesigye, A. Kharel, M.M., G.M., J.L.H.M., F.M., A.M., 
I.M., J.A.N., I.O., M.J.O., B.W.O., T.B.P., L.P., M.R., I.R., T.S., S.E.S., A.T., A.M.T., H.A.T. 
and B.T. implemented the surveys, including training and oversight of enumerators 
and management of sampling for the surveys. S.S.W., N.F.M. and M.T. coordinated the 
project across study samples. The following verified the underlying data for individual 
study samples: E.C. (Burkina Faso, Colombia, Rwanda, Sierra Leone survey 1), B.A. and 
A.B. (India), A.S. and R.L. (Nigeria), A.G., J.S. and M.B.N. (Uganda survey 1), C.M.B. 
and M.H. (Uganda survey 2), N.F.M. and M.V. (Sierra Leone survey 2), G.S. (Russia), 
M.F. (Mozambique), A.Z.F. and J.N.S. (Pakistan survey 1), S. Asad (Pakistan survey 
2), C.V. (Nepal) and N.M. (USA). J.S.S.A., G.S., M.H. and S. Aboutajdine collated and 
processed all datasets used for the analysis. N.F.M., M.H., A.M.M., J.S.S.A., G.S., S.S.W., 
A.S., E.C., E.B., M.T., M.V. and N.M. carried out data interpretation with guidance 
from S.B.O. and A.M. J.S.S.A., G.S., E.C. and M.H. verified final datasets and analysis. 
J.S.S.A. and G.S. performed the data analysis and produced output figures with input 
from M.H., A.M.M., D.K., S.S.W., E.C., M.V., N.F.M. and M.T. M.H. supervised the data 
analysis. J.S.S.A., S.S.W., N.F.M., A.M.M., A.S., N.M. and M.V. wrote the first draft of the 
manuscript, with guidance from A.A.M. and S.B.O. J.S.S.A., S.S.W., N.F.M., A.S., N.M., 
M.V., S. Aboutajdine, E.B., M.R.P., J.N.S., P.C.V., B. Zhang, M.C., M.T., M.H., A.M.M., 
A.A.M. and S.B.O. revised the manuscript. All authors approved the final version of the 
manuscript. All authors had full access to all the data used in this study and had final 
responsibility for the decision to submit for publication.
Competing interests
The authors declare no competing interests.
Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41591-021-01454-y.
Supplementary information The online version contains supplementary material 
available at https://doi.org/10.1038/s41591-021-01454-y.
Correspondence and requests for materials should be addressed to A.M.M. or S.B.O.
Peer review information Nature Medicine thanks Jeffrey Lazarus, Clarissa Simas and 
the other, anonymous, reviewer(s) for their contribution to the peer review of this work. 
Jennifer Sargent was the primary editor on this article and managed its editorial process 
and peer review in collaboration with the rest of the editorial team.
Reprints and permissions information is available at www.nature.com/reprints.
NATuRE MEDICINE | www.nature.com/naturemedicine
ArticlesNATURE MEDICINE
Extended Data Fig. 1 | Trusted sources and institutions, broken down by gender. Figure ED1 shows histograms of sources and institutions that 
respondents say they would trust most to help them decide whether or not to take the COVID-19 vaccine. Respondents were only permitted to select one 
most trusted source or institution. Responses are broken down by gender of respondent.
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Extended Data Fig. 2 | Average vaccine acceptance across all LMIC countries leaving one or two study samples out. Figure ED2 shows distribution of 
estimates of average acceptance for all studies in LMICs (excluding usA and Russia) leaving one and two study samples out at a time. Figure also shows 
distributions of subgroup averages by gender, education and age leaving one and two study samples out at a time. to directly compare the resulting 
distributions to the estimates reported in Fig. 1, we plot point estimates reported in Fig. 1 for all LMIC studies, Russia and the us.
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